Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Company Overview

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Key Stats

• Today's Range: $38.22 to $38.22
• 50-Day Range: $37.81 to $38.25
• 52-Week Range: $19.06 to $40.14
• Volume: N/A
• Average Volume: 1.34 million shs
• Market Capitalization: $2.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DRNA Stock Analysis - Frequently Asked Questions

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DRNA
• CUSIP: N/A
• CIK: 1399529
• Web: www.dicerna.com
• Phone: (617) 621-8097
• Fax: 617-612-6298
• Employees: 302
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-112,750,000.00
• Net Margins: -64.53%
• Pretax Margin: -63.82%
• Return on Equity: -103.08%
• Return on Assets: -16.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.46
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $164.31 million
• Price / Sales: 18.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.84 per share
• Price / Book: 20.77

Miscellaneous

• Outstanding Shares: 78,129,000
• Free Float: 70,160,000
• Market Cap: $2.99 billion
• Optionable: Optionable
• Beta: 0.80